Resources Repository
-
OrganizationWeb Portal 2024RAND Corporation
The RAND Corporation (“Research and Development”) is a research organization that develops solutions to public …
The RAND Corporation (“Research and Development”) is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s research findings and recommendations are based on data and evidence and therefore do not necessarily reflect the policy preferences or interests of its clients, donors, or…
Climate/Environment | Child/Nutrition | Injuries/Accidents | Environmental Health | Policy/Regulation | Business/Industry | Energy/Engineering | Education/Labor | Government/Law | Health/Medicine | Military/Defense | Science/Technology | Global -
OrganizationWeb Portal 2024Results for Development
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems …
Results for Development (R4D) was founded in 2008, with a mission to create self-sustaining systems that support health, educated people, while ensuring that local change agents are in the driver’s seat, and that knowledge is transformed into action. Their work supports sustainable progress in health, education and nutrition, and puts data users at the center of all efforts. They develop tools - including dashboards, scorecards and performance metrics - in a way that is designed to solve practical…
Climate/Environment | Child/Nutrition | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Technology Assessment | Infectious Diseases | Health Systems | Education/Labor | Health/Medicine | Global -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Climate/Environment | Child/Nutrition | Mathematical Models | Dynamic Transmission | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Climate/Environment | Child/Nutrition | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Environmental Health | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa